DOCSLIB.ORG

Approved Drugs • on Aug. 5, the U.S. Food and Drug Administration (FDA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Approved Drugs • on Aug. 5, the U.S. Food and Drug Administration (FDA tools Approved Drugs sideroblasts, refractory anemia with • On June 16, the FDA extended the excess blasts, and chronic indication of Mylotarg™ (gemtuzumab • On Aug. 5, the U.S. Food and Drug myelomonocytic leukemia) and (2) ozogamicin) (Pfizer Inc., Pfizer.com) for Administration (FDA) approved Blenrep intermediate-1, intermediate-2, and newly diagnosed CD33-positive acute (belantamab mafodotin-blmf) high-risk International Prognostic myeloid leukemia to include pediatric (GlaxoSmithKline, gsk.com) for adult Scoring System groups. patients one month and older. patients with relapsed or refractory multiple myeloma who have received at • On June 16, the FDA granted accelerated • On June 11, Pfizer Inc. (pfizer.com) ® least four prior therapies, including an approval to Keytruda (pembrolizumab) announced that the FDA has approved anti-CD38 monoclonal antibody, a (Merck, merck.com) for the treatment of Nyvepria™ (pegfilgrastim-apgf), a proteasome inhibitor, and an immuno- adult and pediatric patients with biosimilar to Neulasta® (pegfilgrastim). unresectable or metastatic tumor modulatory agent. ® mutational burden-high (≥10 mutations/ • On June 10, the FDA approved Opdivo ® • On May 29, the FDA approved Cyramza megabase [mut/Mb]) solid tumors, as (nivolumab) (Bristol Myers Squibb Co., (ramucirumab) (Eli Lilly and Company, determined by an FDA-approved test, bms.com) for patients with unresectable lilly.com) in combination with erlotinib that have progressed following prior advanced, recurrent, or metastatic for first-line treatment of metastatic treatment and who have no satisfactory esophageal squamous cell carcinoma non-small cell lung cancer (NSCLC) with alternative treatment options. On June after prior fluoropyrimidine- and epidermal growth factor receptor (EGFR) 24, the FDA approved Keytruda for platinum-based chemotherapy. exon 19 deletions or exon 21 (L858R) patients with recurrent or metastatic • On June 29, the FDA approved Phesgo™ mutations. cutaneous squamous cell carcinoma that (pertuzumab, trastuzumab, and • On June 12, Merck (merck.com) is not curable by surgery or radiation. On hyaluronidase-zzxf) (Genentech, Inc., announced that the FDA has approved an June 29, the FDA approved Keytruda for gene.com) for subcutaneous injection for expanded indication for Gardasil®9 the first-line treatment of patients with the following indications. The first is use (Human Papillomavirus 9-valent unresectable or metastatic microsatellite of the agent in combination with Vaccine, Recombinant) for the preven- instability-high or mismatch repair chemotherapy as: (1) neoadjuvant tion of oropharyngeal and other head deficient colorectal cancer. treatment of patients with human and neck cancers caused by HPV Types • On July 31, the FDA granted accelerated epidermal growth factor receptor 2 16, 18, 31, 33, 45, 52, and 58. approval to Monjuvi® (tafasitamab-cxix) (HER2)-positive, locally advanced, • On July 7, the FDA approved Inqovi® (MorphoSys US Inc., morphosys.com and inflammatory, or early stage breast (decitabine and cedazuridine) (Astex Incyte, incyte.com), a CD19-directed cancer (either greater than 2 cm in Pharmaceuticals, Inc., astx.com) for adult cytolytic antibody, indicated in combina- diameter or node positive) as part of a patients with myelodysplastic syn- tion with lenalidomide for adult patients complete treatment regimen for early dromes, including the following: (1) with relapsed or refractory diffuse large breast cancer and (2) adjuvant treatment previously treated and untreated, de novo B-cell lymphoma (DLBCL) not otherwise of patients with HER2-positive early and secondary myelodysplastic syn- specified, including DLBCL arising from breast cancer at high risk of recurrence. dromes with the following French- low grade lymphoma, and who are not The second is use of the agent in American-British subtypes (refractory eligible for autologous stem cell combination with docetaxel for anemia, refractory anemia with ringed transplant. treatment of patients with HER2-positive 10 accc-cancer.org | September–October 2020 | OI metastatic breast cancer who have not Drugs in the News • Y-mAbs Therapeutics, Inc. (ymabs.com) received prior anti-HER2 therapy or announced that the BLA for Danyelza™ chemotherapy for metastatic disease. • EMD Serono (emdserono.com/us-en) (naxitamab) for the treatment of announced that the FDA has approved patients with relapsed/refractory • On June 22, the FDA granted accelerated the supplemental biologics license ® high-risk neuroblastoma has been approval to Xpovio (selinexor) ® application (BLA) for Bavencio accepted for priority review by the FDA. (Karyopharm Therapeutics, karyopharm. (avelumab) for the maintenance Leap Therapeutics, Inc. (leaptx.com) com) for adult patients with relapsed or treatment of patients with locally • announced that the FDA has granted refractory diffuse large B-cell lymphoma advanced or metastatic urothelial orphan drug designation for DKN-01 for (DLBCL), not otherwise specified, carcinoma that has not progressed with the treatment of gastric and gastro- including DLBCL arising from follicular first-line platinum-containing esophageal junction cancer. lymphoma, after at least two lines of chemotherapy. systemic therapy. • AVEO Oncology (aveooncology.com) • Black Diamond Therapeutics, Inc. announced that the FDA accepted for • On June 18, the FDA granted accelerated (blackdiamondtherapeutics.com) ™ filing its NDA seeking approval for approval to Tazverik (tazemetostat) announced that the FDA granted fast Fotivda® (tivozanib), a vascular endothe- (Epizyme, Inc., epizyme.com), an track designation to BDTX-189 for the lial growth factor receptor tyrosine enhancer of zeste homolog 2 (EZH2) treatment of adult patients with solid kinase inhibitor as a treatment for inhibitor, for adult patients with relapsed tumors harboring an allosteric HER2 relapsed or refractory renal cell or refractory follicular lymphoma whose mutation or an EGFR or HER2 Exon 20 carcinoma. tumors are positive for an EZH2 insertion mutation who have progressed mutation as detected by an FDA- following prior treatment and who have • Hutchison China MediTech Limited approved test and who have received at no satisfactory treatment options. (chi-med.com) announced that the FDA least two prior systemic therapies and for has granted fast track designation for the adult patients with relapsed or refractory • CNS Pharmaceuticals, Inc. (cnspharma. development of fruquintinib for the follicular lymphoma who have no com) announced that the FDA has treatment of patients with metastatic satisfactory alternative treatment granted orphan drug designation for its colorectal cancer who have been options. lead product Berubicin for the treatment previously treated with fluoropyrimi- of malignant gliomas. dine-, oxaliplatin-, and irinotecan-based • On July 24, the FDA granted accelerated Checkmate Pharmaceuticals, Inc. chemotherapy; an anti-vascular approval to Tecartus™ (brexucabtagene • (checkmatepharma.com) announced endothelial growth factor biological autoleucel) (Kite Pharma, kitepharma. that the FDA granted fast track designa- therapy; and, if RAS wild type, an com), a CD19-directed genetically tion to its product candidate, CMP-001, anti-EGFR therapy. modified autologous T-cell immunother- in combination with a programmed cell apy, for the treatment of adult patients • Bristol Myers Squibb (bms.com) and death receptor 1 (PD-1) blocking with relapsed or refractory mantle cell bluebird bio, Inc. (bluebirdbio.com) antibody (nivolumab or pembrolizumab) lymphoma. announced the submission of their BLA for two development programs, to the FDA for idecabtagene vicleucel • On July 31, Roche (roche.com) announced including initial treatment of patients (ide-cel; bb2121), the companies’ ® that the FDA approved Tecentriq with unresectable Stage III or Stage IV investigational B-cell maturation ® (atezolizumab) plus Cotellic melanoma to prolong the time to disease antigen-directed chimeric antigen ® (cobimetinib) and Zelboraf progression and treatment of patients receptor T-cell immunotherapy, for the (vemurafenib) for the treatment of BRAF with unresectable or metastatic treatment of adult patients with relapsed V600 mutation-positive advanced melanoma refractory to prior anti-PD-1 and refractory multiple myeloma. melanoma patients. blockade to improve the overall tumor • Merck (merck.com) announced that the response rate. • On June 15, Jazz Pharmaceuticals plc FDA accepted and granted priority review (jazzpharma.com) and its partner • Celyad Oncology SA (celyad.com) for a new supplemental BLA for Key- PharmaMar (pharmamar.com) announced that the company’s investi- truda® (pembrolizumab) as monother- announced that the FDA approved gational new drug application (NDA) for apy for the treatment of adult patients Zepzelca™ (lurbinectedin) for the CYAD-211, a short hairpin RNA (shR- with relapsed or refractory classical treatment of adult patients with NA)-based allogeneic chimeric antigen Hodgkin lymphoma. The company also metastatic small cell lung cancer with receptor T candidate and second announced that the FDA has accepted disease progression on or after non-gene edited off-the-shelf program, is and granted priority review for a new platinum-based chemotherapy. in effect with the FDA. supplemental BLA seeking accelerated OI | September–October 2020 | accc-cancer.org 11 approval for Keytruda in combination submission of an NDA to the FDA for • Roche (roche.com) announced FDA with chemotherapy for the treatment of pralsetinib
Load more

Recommended publications
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria
    Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria HEALTH SYSTEMS DIVISION Prior authorization (PA) criteria for fee-for-service prescriptions for Oregon Health Plan clients March 1, 2021 Contents Contents ................................................................................................................................................................ 2 Introduction........................................................................................................................................................... 7 About this guide ......................................................................................................................................... 7 How to use this guide ................................................................................................................................. 7 Administrative rules and supplemental information .................................................................................. 7 Update information............................................................................................................................................... 8 Effective March 1, 2021 ............................................................................................................................ 8 Substantive updates and new criteria ............................................................................................. 8 Clerical changes ............................................................................................................................
    [Show full text]
  • Refreshing the Biologic Pipeline 2020
    news feature Credit: Science Lab / Alamy Stock Photo Refreshing the biologic pipeline 2020 In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay. John Hodgson OVID-19 might have been expected since 1996) — a small miracle in itself “COVID-19 confronted us with the need to severely impair drug approvals (Fig. 1 and Table 1). to better triage sponsors’ questions,” says Cin 2020. In the event, however, To the usual crop of rare disease and Peter Marks, the director of the Center for industry and regulators delivered a small genetic-niche cancer treatments, 2020 Biologics Evaluation and Research (CBER) miracle. They found workarounds and also added a chimeric antigen receptor at the FDA. “That was perhaps the single surrogate methods of engagement. Starting (CAR)-T cell therapy with a cleaner biggest takeaway from the pandemic related in January 2020, when the outbreak veered manufacturing process and the first to product applications.” Marks says that it westward, the number of face-to face approved blockbuster indication for a became very apparent with some COVID- meetings declined rapidly; by March, small-interfering RNA (siRNA) — the 19-related files that resolving a single they were replaced by Webex and Teams. European Medicines Agency’s (EMA) issue can help a sponsor enormously and (Secure Zoom meeting are to be added registration of the RNA interference accelerate the development cycle. Before this year.) And remarkably, by 31 December, (RNAi) therapy Leqvio (inclisiran) for COVID-19, it was conceivable that a small the US Food and Drug Administration cardiovascular disease.
    [Show full text]
  • Full Prescribing Information [FDA]
    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------------CONTRAINDICATIONS------------------------------ These highlights do not include all the information needed to use None. MONJUVI safely and effectively. See full prescribing information for MONJUVI. ------------------------WARNINGS AND PRECAUTIONS----------------------- Infusion-Related Reactions: Monitor patients frequently during infusion. MONJUVI® (tafasitamab-cxix) for injection, for intravenous use Interrupt or discontinue infusion based on severity. (2.3, 5.1) Initial U.S. Approval: 2020 Myelosuppression: Monitor complete blood counts. Manage using dose modifications and growth factor support. Interrupt or discontinue -----------------------------INDICATIONS AND USAGE-------------------------- MONJUVI based on severity. (2.3, 5.2) MONJUVI is a CD19-directed cytolytic antibody indicated in combination Infections: Bacterial, fungal and viral infections can occur during and with lenalidomide for the treatment of adult patients with relapsed or following MONJUVI. Monitor patients for infections. (2.3, 5.3) refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, Embryo-Fetal Toxicity: May cause fetal harm. Advise females of including DLBCL arising from low grade lymphoma, and who are not eligible reproductive potential of the potential risk to a fetus and use of effective for autologous stem cell transplant (ASCT). contraception. (5.4) This indication is approved under accelerated approval based on overall -------------------------------ADVERSE
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Chemotherapy: Drugs E-O Policy (Chemo Drug E-O)
    chemo drug e-o 1 Chemotherapy: Drugs E-O Policy Page updated: September 2020 This section contains policy related to billing for injection services, listed in alphabetical order by generic drug name or drug type. For general billing policy information regarding injections services, refer to the Chemotherapy: An Overview section in this manual. Additional policy information for chemotherapy drug services can be found in the Chemotherapy: Drugs A-D Policy and Chemotherapy: Drugs P-Z Policy sections in this manual. Elotuzumab Elotuzumab is a humanized IgG1 monoclonal antibody that specifically targets the SLAMF7 (signaling lymphocytic activation molecule family member 7) protein. SLAMF7 is expressed on myeloma cells independent of cytogenetic abnormalities. SLAMF7 is also expressed on natural killer cells, plasma cells and at lower levels on specific immune cell subsets of differentiated cells within the hematopoietic lineage. Elotuzumab directly activates natural killer cells through both the SLAMF7 pathway and Fc receptors. Elotuzumab also targets SLAMF7 on myeloma cells and facilitates the interaction with natural killer cells to mediate the killing of myeloma cells through antibody-dependent cellular cytotoxicity (ADCC). Indications Elotuzumab is indicated in combination with lenalidomide and dexamethasone for the treatment of patients ages 18 years or older, with multiple myeloma who have received one to three prior therapies. Pre-medicate with dexamethasone, diphenhydramine, ranitidine and acetaminophen. Advise patients that lenalidomide has the potential to cause fetal harm. Authorization An approved Treatment Authorization Request (TAR) is required for reimbursement. The TAR must state that the treatment is for a patient with multiple myeloma who has received one to three prior therapies.
    [Show full text]
  • Corporate Medical Policy Tafasitamab-Cxix (Monjuvi®)
    Corporate Medical Policy Tafasitamab-cxix (Monjuvi®) File Name: tafasitamab_monjuvi Origination: 10/2020 Last CAP Review: 1/2021 Next CAP Review: 1/2022 Last Review: 1/2021 Description of Procedure or Service Tafasitamab-cxix (Monjuvi®) is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). DLBCL is the most common subtype of non-Hodgkin lymphoma (NHL), representing approximately one-third of NHL patients. It is an aggressive and quickly progressing NHL in which survival without treatment is measured in months. While there have been many advancements in the treatment of DLBCL, a cure is not achieved in most patients using conventional therapy, and roughly 30 to 40% of patients suffer relapse. For patients who are refractory to initial treatment and for patients who relapse after an initial response, only a small percentage will experience prolonged disease-free survival with salvage chemoimmunotherapy treatment alone. The preferred treatment for a first relapse of DLBCL or primary refractory DLBCL is salvage chemoimmunotherapy followed by autologous hematopoietic stem cell transplantation (HSCT). However, the outcome for relapsed/refractory DLBCL patients who are ineligible for transplant remains poor. Tafasitamab-cxix (Monjuvi) is a humanized CD19-directed cytolytic monoclonal antibody, which was approved by the U.S. Food and Drug Administration (FDA) in July 2020 for the treatment of relapsed or refractory DLBCL. It works by binding to CD19 expressed on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including DLBCL, which induces B-cell lysis via apoptosis and immune effector mechanisms.
    [Show full text]
  • Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
    pharmaceutics Review Antibodies for the Treatment of Brain Metastases, a Dream or a Reality? Marco Cavaco, Diana Gaspar, Miguel ARB Castanho * and Vera Neves * Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal * Correspondence: [email protected] (M.A.R.B.C.); [email protected] (V.N.) Received: 19 November 2019; Accepted: 28 December 2019; Published: 13 January 2020 Abstract: The incidence of brain metastases (BM) in cancer patients is increasing. After diagnosis, overall survival (OS) is poor, elicited by the lack of an effective treatment. Monoclonal antibody (mAb)-based therapy has achieved remarkable success in treating both hematologic and non-central-nervous system (CNS) tumors due to their inherent targeting specificity. However, the use of mAbs in the treatment of CNS tumors is restricted by the blood–brain barrier (BBB) that hinders the delivery of either small-molecules drugs (sMDs) or therapeutic proteins (TPs). To overcome this limitation, active research is focused on the development of strategies to deliver TPs and increase their concentration in the brain. Yet, their molecular weight and hydrophilic nature turn this task into a challenge. The use of BBB peptide shuttles is an elegant strategy. They explore either receptor-mediated transcytosis (RMT) or adsorptive-mediated transcytosis (AMT) to cross the BBB. The latter is preferable since it avoids enzymatic degradation, receptor saturation, and competition with natural receptor substrates, which reduces adverse events. Therefore, the combination of mAbs properties (e.g., selectivity and long half-life) with BBB peptide shuttles (e.g., BBB translocation and delivery into the brain) turns the therapeutic conjugate in a valid approach to safely overcome the BBB and efficiently eliminate metastatic brain cells.
    [Show full text]
  • 2020 End of the Year Summary Report-2 FDA Approved 13 New Large Molecule Drugs and 2 New Gene Therapy Products
    2020 End of the Year Summary Report-2 FDA Approved 13 New Large Molecule Drugs and 2 New Gene Therapy Products BLA Regulatory, LLC (Gaithersburg, MD) provides the following summary of 2020 FDA approved new large molecule (LM) drugs and gene therapy products. Reviewers/Readers are suggested to open FDA links for detailed information and accuracy. Number of approved LM drugs and Gene Therapies in sub-categories Therapeutic Area Formulation Regulatory Program Oncology 6 IV Solution 11 Breakthrough Therapy 2 Genetic disorder 3 Subcutaneous Solution 3 Fast Track 1 Neurology 2 Lyophilized powder 1 Orphan Drug 11 Infection 2 Priority Review 3 Metabolic disease 1 Ophthalmology 1 Page 1 of 6 If re-sharing and re-printing, please indicate BLA as the source of this summary. Number New Drug Sponsor indication Drug Regulatory Unique clinical design Details Approve formulation target special Date program 1 TEPEZZA Horizon Treatment of IGF-1R Priority "There were two randomized, double-masked, placebo-controlled trials that FDA link 1/21 (teprotumum Pharma Thyroid Eye Review, provided data for approval of TEPEZZA. ab-trbw) Ireland, Disease Fast Track, Ltd. Breakthrou Patients with active thyroid eye disease received TEPEZZA by intravenous Lyophilized gh Therapy infusions (10 mg/kg for first infusion and 20 mg/kg for the remaining 7 powder for Designation infusions) or placebo infusions every 3 weeks for a total of 8 infusions. intravenous and Orphan infusion Drug The main outcome measure was the proptosis responder rate at week 24 designation defined as the percentage of patients with ≥2 mm reduction in proptosis in LM the study eye from baseline, without deterioration in the non-study eye (≥2 mm increase)." 2 VYEPTI Lundbeck The preventive CGRP N/A "The efficacy and safety of VYEPTI were evaluated in two similar, FDA Link 2/21 (eptinezuma Seattle treatment of randomized, multicenter, placebo-controlled clinical trials.
    [Show full text]
  • Cantargia Strengthens the Company Management Team
    Press release Cantargia AB 556791-6019 1 September 2021 Cantargia strengthens the company management team Cantargia AB (publ) (Cantargia) announced today that Nedjad Losic has been employed as VP Biometrics at Cantargia from 1 September 2021. He will be part of the management team where he will contribute with his extensive experience, from e.g. development of daratumumab at Genmab, of antibodies for cancer treatment. Cantargia's research portfolio has developed well, and preparations are underway to advance to late stage clinical development phase. In connection with this, the management team has been strengthened in statistics, and data management, two future key activities. Nedjad Losic has unique competence in these areas and will take responsibility for both. Nedjad Losic, who most recently held a position at Y-mAbs Therapeutics Inc., has 25 years of experience in pharmaceutical drug development, including 16 years with antibodies in oncology. He had key roles in the development and market approvals of daratumumab (multiple myeloma), ofatumumab (chronic lymphocytic leukemia) and naxitamab (neuroblastoma). Nedjad has also been CEO at Spadille Sweden as well as Board Member of Genmab A/S. He holds a M. Sc. in Mathematics, from the University of Lund. “We are pleased to have Nedjad in Cantargia's organization. With his extensive experience from development of antibodies for cancer treatment and interactions with regulatory authorities, he will have an important function in the company when we take the next step in the clinical development program with our main project nadunolimab," says Göran Forsberg, CEO of Cantargia. For further information, please contact Göran Forsberg, CEO Telephone: +46 (0)46-275 62 60 E-mail: [email protected] The information was submitted for publication at 09.00 CET on 1 September 2021.
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]